VCAN and non-small cell lung carcinoma: Similarly, compared with low plasma exosomal versican, the risk of NSCLC with high plasma exosomal versican was 3.083 (95%CI 1.414–6.726, P = 0.005), and the adjusted OR was 1.871 (95%CI 0.439–7.961, P > 0.05) (Fig. 8C and D ).